NCT02304302: A trial that was reported late by University Hospitals Cleveland Medical Center
This trial has reported, although it was 153 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02304302 |
|---|---|
| Title | Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Oct. 31, 2014 |
| Completion date | July 22, 2020 |
| Required reporting date | July 22, 2021, midnight |
| Actual reporting date | Dec. 22, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 153 |